Lupin has received approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.
Lupin’s Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, is the generic equivalent of Eli Lilly and company’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg (RLD: Cialis) had annual sales of approximately $1780 million in the US (IQVIA MAT December 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
